荧光原位杂交（FISH）与免疫组织化学（IHC）检测122例疑难胃癌病例中HER2基因扩增情况的比较
HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases.
作者信息
Liu Xiaoyan, Wang Xiaoling, Wang Bo, Ren Guoping, Ding Wei
机构信息
Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
出版信息
Appl Immunohistochem Mol Morphol. 2016 Aug;24(7):459-64. doi: 10.1097/PAI.0000000000000219.
OBJECTIVE
To determine the frequency of HER2/neu amplification and the relationship between HER2/neu expression and clinicopathologic features in gastric cancers scored immunohistochemistry (IHC) 2+.
METHODS
A total of 122 gastric cancer cases scored IHC 2+ were retrospectively analyzed for HER2 amplification by fluorescence in situ hybridization (FISH). The correlation between HER2/neu expression and clinicopathologic features was analyzed.
RESULTS
HER2/neu gene was amplified in 17 out of the 122 gastric cancer samples. The concordance rate between IHC and FISH was 13.9%. HER2/neu status was correlated with the age of patients (P<0.05). Polysomy of CEP17 was demonstrated in 46 cases, 11 of which (23.91%) were amplified for HER2/neu. Within the subgroups, a correlation between CEP17 polysomy and the depth of invasion was observed (P<0.05).
CONCLUSIONS
The results highlight the necessity of FISH test for further categorization when gastric cancer cases are scored 2+ by IHC. The value of HER2/neu for a potential role as a negative prognostic factor in the equivocal gastric cancer cases is limited.
目的
确定免疫组织化学（IHC）评分为2+的胃癌中HER2/neu扩增的频率以及HER2/neu表达与临床病理特征之间的关系。
方法
对122例IHC评分为2+的胃癌病例进行回顾性分析，采用荧光原位杂交（FISH）检测HER2扩增情况。分析HER2/neu表达与临床病理特征之间的相关性。
结果
122例胃癌样本中有17例HER2/neu基因扩增。IHC与FISH的一致性率为13.9%。HER2/neu状态与患者年龄相关（P<0.05）。46例显示有17号染色体着丝粒（CEP17）多体性，其中11例（23.91%）HER2/neu扩增。在亚组中，观察到CEP17多体性与浸润深度之间存在相关性（P<0.05）。
结论
结果强调，当胃癌病例IHC评分为2+时，FISH检测对于进一步分类的必要性。在模棱两可的胃癌病例中，HER2/neu作为潜在阴性预后因素的价值有限。
Zotero 插件